Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.50 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.50 |
| ▸ | HTR3B | O95264 | 1/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.50 |
| ▸ | HTR3A | P46098 | 1/20 | 0.50 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.50 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2855093 | 0.87 | MAPT (0.42) | MAPTLMNASIGMAR1CHRNA7HTR3E | |
| SCHEMBL7678643 | 0.83 | DRD4 (0.50) | MAPTLMNASIGMAR1CHRNA7HTR3E | |
| SCHEMBL16924853 | 0.83 | LMNA (0.67) | MAPTLMNASIGMAR1CHRNA7HTR3E | |
| SCHEMBL576454 | 0.83 | LMNA (0.67) | MAPTLMNASIGMAR1CHRNA7HTR3E | |
| SCHEMBL164538 | 0.83 | LMNA (0.67) | MAPTLMNASIGMAR1CHRNA7HTR3E | |
| SCHEMBL385012 | 0.83 | — | — | |
| SCHEMBL576814 | 0.83 | LMNA (0.67) | MAPTLMNASIGMAR1CHRNA7HTR3E | |
| SCHEMBL4432185 | 0.81 | LMNA (0.57) | MAPTLMNASMN1; SMN2GAARAB9A | |
| SCHEMBL7258870 | 0.80 | LMNA (0.64) | MAPTLMNASIGMAR1CHRNA7HTR3E | |
| SCHEMBL4052281 | 0.77 | AKR1C3 (0.52) | MAPTLMNASIGMAR1CHRNA7HTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420638-B2 | Triheterocyclic compounds and compositions thereof | GEMIN X PHARMACEUTICALS CANADA INC. (CA) | 2013-04-16 | — | — | US | disclosed |
| US-8420638-B2 | Triheterocyclic compounds and compositions thereof | GEMIN X PHARMACEUTICALS CANADA INC. (CA) | 2013-04-16 | — | — | US | disclosed |
| US-20120004224-A1 | Triheterocyclic Compounds and Compositions Thereof | Gemin X Pharmaceuticals Canada Inc. (formerly Gemin X Biotechnologies Inc.) | 2012-01-05 | — | — | US | disclosed |
| US-20120004224-A1 | Triheterocyclic Compounds and Compositions Thereof | Gemin X Pharmaceuticals Canada Inc. (formerly Gemin X Biotechnologies Inc.) | 2012-01-05 | — | — | US | disclosed |
| US-7709477-B2 | Methods for treating cancer | GEMIN X PHARMACEUTICALS CANADA INC. (CA) | 2010-05-04 | — | — | US | disclosed |
| US-20080318903-A1 | METHODS FOR TREATING CANCER | GEMIN X PHARMACEUTICALS CANADA INC. (CA) | 2008-12-25 | — | — | US | disclosed |
| US-20080318902-A1 | TRIHETEROCYCLIC COMPOUNDS AND COMPOSITIONS THEREOF | GEMIN X PHARMACEUTICALS CANADA INC. (CA) | 2008-12-25 | — | — | US | disclosed |
| US-20080318902-A1 | TRIHETEROCYCLIC COMPOUNDS AND COMPOSITIONS THEREOF | GEMIN X PHARMACEUTICALS CANADA INC. (CA) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318903-A1 | METHODS FOR TREATING CANCER | HCCS, EIF2AK2, ZC3HAV1 | MAPT 4782/4885LMNA 2399/4885SIGMAR1 4443/4885 |
| US-20080318902-A1 | TRIHETEROCYCLIC COMPOUNDS AND COMPOSITIONS THEREOF | ZC3HAV1, HCCS, PCNA | MAPT 4605/4885LMNA 1751/4885SIGMAR1 4493/4885 |
| US-20120004224-A1 | Triheterocyclic Compounds and Compositions Thereof | ZC3HAV1, HCCS, PCNA | MAPT 4605/4885LMNA 1751/4885SIGMAR1 4493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.